Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells

PURPOSE: Continuous reductions in trabecular meshwork (TM) cellularity inhibit aqueous humor (AH) outflow, which is the main cause of primary open-angle glaucoma. Rho-associated protein kinase inhibitor (ROCKi) targets the TM to reduce intraocular pressure (IOP) and increase AH outflow facility. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenshi, Yang, Xuejiao, Fang, Jingwang, Zhang, Yuqing, Zhu, Wei, Yang, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090161/
https://www.ncbi.nlm.nih.gov/pubmed/32256367
http://dx.doi.org/10.3389/fphar.2020.00302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090161/
https://www.ncbi.nlm.nih.gov/pubmed/32256367
http://dx.doi.org/10.3389/fphar.2020.00302

Ejemplares similares